Loading company
Cytokinetics Inc.
CYTK · Nasdaq · ·
Next earnings: November 4, 2026
$65.67-0.7%Sep 29 close
- 1M
- -8.9%
- 6M
- +4.3%
- 1Y
- +19.5%
- 5Y
- +88.1%
CYTK · Nasdaq · ·
Next earnings: November 4, 2026
$65.67-0.7%Sep 29 close
Cytokinetics Inc. is scheduled to report next on November 4, 2026. The date comes from Nasdaq’s earnings calendar, and companies sometimes move it.
The quarter ending June 30, 2026, against the same quarter a year earlier.
| Measure | 3 months toJun 30, 2026 | 3 months toJun 30, 2025 | Change |
|---|---|---|---|
| Total Revenue | $28.6M | $66.8M | -57.13% |
| Profit | -$198.8M | -$134.4M | -47.92% |
| Profit per share | -$1.50 | -$1.12 | -33.93% |
| Free Cash Flow | -$164.2M | -$132.4M | -24.02% |
These are single quarters, not a trailing year — the figures elsewhere on this site cover twelve months and will be much larger. A seasonal business swings a long way between the two: ServiceNow earns $2.0B of free cash flow in its December quarter and $0.5B in its June one.
Compared against the same quarter a year earlier, not against an analyst forecast. A “beat” or “miss” needs a consensus estimate, which is licensed data we do not carry — and getting it wrong is worse than leaving it out.
“Our second quarter results demonstrate commercial launch momentum for MYQORZO alongside continued excellence for our development pipeline, both hallmarks of continued strong execution for our maturing business. In the U.S., we continued to build launch velocity evidenced by expanding physician adoption and increasing patient access. Internationally, we launched MYQORZO in Germany and laid the foundation for broadening access to aficamten by submitting reimbursement dossiers alongside regulatory filings advancing in multiple countries in Europe,”
Quoted verbatim from the release, and shown only when the filing attributes it to a named person.
Releases land after the close or before the open, so the move is the session that follows.
The quote and the company description come from Cytokinetics Inc.’s Item 2.02 8-K filed August 6, 2026; the table is built from its quarterly reports. Read the release on EDGAR Share prices are split- and dividend-adjusted.
Cytokinetics Inc. has no earnings call transcript available.